Licartin (Iodine-131-labeled metuximab) / Chengdu Huasun Biotechnology - LARVOL DELTA

Analysis of factors influencing the distribution of 131-I in combined treatment of Licartin with transcatheter arterial chemoembolization in primary hepatic carcinoma. (PubMed, Front Oncol) - "In 13 cases (31.7%), there was lower aggregation in the tumor than in the normal liver, which was related to the selected vessels in the Licartin perfusion (OR=0.23,P = 0.013). The effective aggregation of 131-I in the liver, even in tumors, the previous history of TACE, and the choice of vessels in the Licartin infusion might be the factors influencing the distribution of 131-I in the liver during hepatic artery infusion of Licartin in combination with TACE therapy."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials. (PubMed, Cancers (Basel)) - "Clinical trials also demonstrated the potential of some antibody formats, such as F(ab'), which has already been approved by the China State FDA under the trend name Licartin®. Despite disparate results, mAb fragments are an interesting prospect for the improvement of RIT efficiency as well as for pretargeted strategies that delay the injection of radioactive treatments from the mAb ones."

Clinical • Journal • Review • Bone Marrow Transplantation • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • Transplantation

Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer. (PubMed, J BUON) - "Licartin combined with TACE has better efficacy than TACE alone in the treatment of middle-advanced primary liver cancer, with tolerable adverse reactions, which prolongs patients' survival time."

Clinical • Journal • Gastrointestinal Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • AFP • CTCs

A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma (clinicaltrials.gov) - P4; N=120; Recruiting; Sponsor: Tianjin Medical University Cancer Institute and Hospital; Trial primary completion date: Nov 2015 ➔ Nov 2016

Trial primary completion date • Biosimilar • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology